Literature DB >> 10642043

Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients.

I Jambaqué1, C Chiron, C Dumas, J Mumford, O Dulac.   

Abstract

Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis. Our first objective was to evaluate the cognitive long term effect outcome of children whose refractory spasms definitely disappeared when VGB was given as an add on drug. Our second objective was to determine the response of generalized epilepsy (infantile spasms) compared to partial epilepsy on cognitive impairment. A non selected series of 13 children underwent psychometric and behavioural evaluation before VGB initiation at a mean of 3 years on VGB treatment. Eight of them could perform detailed neuropsychological tests at follow-up. Seven had infantile spasms (Group I), they all were spasm free before 2 years of age and five remained with rare partial seizures (mean age, 5.5 years). Six others had partial epilepsy without spasms (Group II) and five remained with rare seizures (mean age, 7.5 years). Patients of Group I experienced dramatic changes. Developmental quotient (DQ) significantly rose in six out of seven by ten to more than 45 points (P = 0.03) and autistic behaviour disappeared in five out of the six who presented with. The four tested children had normal verbal level after 5 years and could integrate at school but they remained with marked visuospatial disabilities. By contrast, patients of Group II remained with an unchanged DQ of about 60 so that both groups had similar DQ levels on follow-up. The cessation of spasms with VGB is therefore associated with significant improvement of cognition and behaviour in children with tuberous sclerosis. Controlling secondary generalization induced by infantile spasms seems to be a key factor for mental development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642043     DOI: 10.1016/s0920-1211(99)00082-0

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  36 in total

1.  In search of epilepsy biomarkers in the immature brain: goals, challenges and strategies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis.

Authors:  Petrus de Vries; Ayla Humphrey; Deborah McCartney; Penny Prather; Patrick Bolton; Ann Hunt
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-07       Impact factor: 4.785

Review 3.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

4.  Epilepsy: Vigabatrin treatment and visual field loss.

Authors:  Catherine Chiron; Olivier Dulac
Journal:  Nat Rev Neurol       Date:  2011-03-01       Impact factor: 42.937

5.  AMPA receptor antagonist NBQX attenuates later-life epileptic seizures and autistic-like social deficits following neonatal seizures.

Authors:  Jocelyn J Lippman-Bell; Sanjay N Rakhade; Peter M Klein; Makram Obeid; Michele C Jackson; Annelise Joseph; Frances E Jensen
Journal:  Epilepsia       Date:  2013-10-01       Impact factor: 5.864

Review 6.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 7.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

8.  CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.

Authors:  Stephen W Briggs; Wenzhu Mowrey; Charles B Hall; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2013-10-28       Impact factor: 5.864

Review 9.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

10.  Increased white matter gyral depth in dyslexia: implications for corticocortical connectivity.

Authors:  Manuel F Casanova; Ayman S El-Baz; Jay Giedd; Judith M Rumsey; Andrew E Switala
Journal:  J Autism Dev Disord       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.